Exploring volanesorsen: a promising approach to preventing acute pancreatitis in severe hypertriglyceridemia
Julien Moury,Gauthier Nendumba,Arnaud Robert,Benedicte Hauqiert,Ovidiu Vornicu,Sydney Blackman,Emily Perriens,Maha Bendoumou,Anaïs Carrasco Sanchez,Emma Buttice,Amina El Bachti,David Vidal Bankier,Simrane Gurdina,Anne-Sophie Dincq,Patrick Evrard,Pierre Bulpa,Isabelle Michaux,Patrick M. Honore
DOI: https://doi.org/10.21037/atm-24-63
IF: 3.616
2024-10-19
Annals of Translational Medicine
Abstract:Julien Moury 1 , Gauthier Nendumba 1 , Arnaud Robert 1 , Benedicte Hauqiert 1 , Ovidiu Vornicu 1,2 , Sydney Blackman 3 , Emily Perriens 4 , Maha Bendoumou 4 , Anaïs Carrasco Sanchez 4 , Emma Buttice 4 , Amina El Bachti 4 , David Vidal Bankier 4 , Simrane Gurdina 4 , Anne-Sophie Dincq 1,2 , Patrick Evrard 1 , Pierre Bulpa 1 , Isabelle Michaux 1 , Patrick M. Honore 1 1 ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 2 ICU and Anesthesiology Departments, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 3 Department of Gynecology, Centre Interegional Edith Cavell (CHIREC), Brussels, Belgium; 4 ULB University, Brussels, Belgium Comment on: Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, et al . Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia. N Engl J Med 2024;390:476-7. Keywords: Severe hypertriglyceridemia (sHTG); acute pancreatitis (AP); volanesorsen Submitted Mar 29, 2024. Accepted for publication Aug 16, 2024. Published online Sep 21, 2024. doi: 10.21037/atm-24-63 Alexander et al. recently discussed a novel treatment approach for preventing acute pancreatitis (AP) in patients with severe hypertriglyceridemia (sHTG) (1). sHTG is established with a triglyceride (TG) quantity of ≥500 mg/dL according to American literature (2,3). Research indicates it is reasonable to target fasting serum TG below 500 mg/dL to prevent hyper triglyceridemic pancreatitis (4). It is a significant risk factor for AP and contributes to approximately 10% of pancreatitis cases. The risk of AP is proportional to the plasma levels of TG-rich lipoproteins and chylomicrons (5). The classical reason for increased TG is multifactorial chylomicronemia (MCM). This state is induced by gene modifications and by nourishment containing too much adipose tissue and simple carbohydrates. Other states induce MCM too are overweight, drinking ethanol, and uncontrolled diabetes (6). Although the Food and Drug Administration (FDA) has granted approval for fibrates, n-3 fatty acids, and niacin to treat sHTG, the evidence substantiating their effectiveness in reducing the occurrence of AP remains inadequate. Furthermore, there is a notable absence of evidence indicating a decreased incidence of AP among patients undergoing pharmacologic interventions to lower TG levels (1). Apo-CIII is a little glycoprotein made up of 79 amino acids, conceal by the APOC3 gene. It raises TG by lowering lipoprotein lipase (LPL) activity, impede TG elimination from the plasma, boost liver very-low-density lipoprotein (VLDL) production going into the plasma, and promoting foster sub-endothelial storage of low-density lipoprotein (LDL) (7). Research has indicated that mutations causing loss of function in the APOC3 gene are associated with low TG levels and a reduced risk of ischemic cardiovascular disease (8,9). Consequently, seeking a treatment targeting APOC3 to reduce apo-CIII concentrations and TG levels was a logical step in sHTG treatment development. Volanesorsen, the first antisense oligonucleotide planned to aim APOC3, handle by impeding APOC3 mRNA, leading in a cutting of apo-CIII production by liver cells (10). To the best of our knowledge, there are three major clinical trials on volanesorsen in the literature. The APPROACH study, the initial phase 3 patient study on volanesorsen, was a multi-center, double-blind, randomized, placebo-controlled carried out on 66 patients during a 52-week interval. Its objective was to determine whether the use of volanesorsen was related with a reduction in TG amounts compared to placebo in patients with MCM. At 90 days, patients receiving volanesorsen 300 mg once a week showed a 77% decrease in TG amounts, compared to an 18% rise in the placebo group. The treatment effects of volanesorsen were sustained for 6 months, at which time TG levels were lower by a mean of 53% in the volanesorsen group, compared to a 25% mean increase in the placebo arm. At 12 months, TG amounts were lowered by 40% in the volanesorsen arm, whereas amounts in the placebo arm raised increased by 9%. The placebo arm did undergo AP episodes, with five episodes in three patients, while the treatment arm group did not undergo any such episodes (11). The placebo arm undergoes AP episodes, with five episodes in three patients, while the treatment arm did not undergo any such episodes (11). The COMPASS trial, another pivotal study, was a multi-center, randomized, double-blind, placebo-controlled study realized in 114 patients with fasting plasma TG >500 mg/dL over a period of 52 weeks. The aim was to examine if treatment with volanesorsen, compared t -Abstract Truncated-
oncology,medicine, research & experimental